116 related articles for article (PubMed ID: 3213197)
1. [Results and prospects of the combined and complex treatment of cancer of the bladder].
Dunchik VN; Kariakin OB
Vestn Akad Med Nauk SSSR; 1988; (6):44-50. PubMed ID: 3213197
[No Abstract] [Full Text] [Related]
2. Surgery and intravesical chemotherapy in the management of superficial bladder cancer.
Soloway MS
Semin Urol; 1983 Feb; 1(1):23-33. PubMed ID: 6433424
[No Abstract] [Full Text] [Related]
3. [Our experience in treating patients with surface cancer of the bladder].
Matveev BP; Figurin KM; Romanov VA; Cheban NL
Urol Nefrol (Mosk); 1995; (5):35-8. PubMed ID: 8571484
[TBL] [Abstract][Full Text] [Related]
4. Superficial bladder cancer--treatment approach.
Abi-Aad A; Biquet P; Penders L
Acta Urol Belg; 1996 May; 64(2):19-24. PubMed ID: 8701801
[No Abstract] [Full Text] [Related]
5. [Current prospects and possibilities of the combined and complex treatment of tumors of the bladder].
Mokhort VA; Strotskiĭ AV
Vestn Akad Med Nauk SSSR; 1988; (6):50-4. PubMed ID: 3213198
[No Abstract] [Full Text] [Related]
6. Treatment of superficial bladder cancer.
Grossman HB
Compr Ther; 1995 May; 21(5):245-8. PubMed ID: 7621655
[No Abstract] [Full Text] [Related]
7. [BCG therapy. Its role in the treatment of tumors of the bladder].
Patard JJ; Chopin DK; Abbou CC
Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911
[No Abstract] [Full Text] [Related]
8. [Intravesical BCG therapy for superficial bladder cancer].
Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
[TBL] [Abstract][Full Text] [Related]
9. When is a cystectomy necessary in carcinoma in situ?
Herr HW
Prog Clin Biol Res; 1989; 303():511-5. PubMed ID: 2780659
[No Abstract] [Full Text] [Related]
10. Carcinoma of the urinary bladder category T3 NX MO treated by preoperative irradiation followed by simple cystectomy.
van der Werf-Messing BH; Friedell GH; Menon RS; Hop WC; Wassif SB
Prog Clin Biol Res; 1988; 260():453-60. PubMed ID: 3129735
[No Abstract] [Full Text] [Related]
11. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
12. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
13. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
15. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
17. [Intravesical therapy: Influence on superficial bladder cancer progression].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169
[TBL] [Abstract][Full Text] [Related]
18. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
19. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
20. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
